Minirin (Desmopressin)

Desmopressin is a synthetic analogue of the natural hormone vasopressin. It selectively activates V2 receptors on renal collecting‑duct cells, which triggers a cascade that increases cyclic AMP and promotes the insertion of aquaporin‑2 water channels into the tubular membrane, allowing more water to be reabsorbed. In blood vessels, V2 activation releases stored clotting factors, enhancing haemostasis.

The dose of Minirin is individualized by the prescribing clinician based on the specific indication, patient age, weight, renal function and response to therapy. Dosage adjustments are made according to clinical monitoring of urine output, serum sodium levels and, when used for haemostatic purposes, factor VIII or von Willebrand factor activity.

Safety data for desmopressin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should weigh potential benefits against possible risks and discuss use with the patient. Breastfeeding mothers should consult their physician before starting therapy.

To request Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

The primary alternative to desmopressin is natural vasopressin, which has a broader receptor profile and a shorter half‑life, leading to more frequent dosing and higher risk of cardiovascular side effects. Desmopressin’s selective V2 activity provides longer‑lasting antidiuretic and haemostatic effects with a more favorable safety profile for chronic use.

Minirin sublingual tablets should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Minirin is taken as a sublingual tablet. The tablet is placed under the tongue and allowed to dissolve completely without swallowing water for at least 5‑10 minutes. Patients should avoid eating or drinking immediately after administration to ensure optimal absorption.

The most critical safety concerns are severe hyponatraemia and water intoxication, which can lead to cerebral oedema, seizures, or coma. Patients should be educated to limit excessive fluid intake and to report symptoms such as headache, nausea, confusion, or sudden weight gain promptly.

Minirin is contraindicated in individuals with uncontrolled hyponatraemia, severe renal impairment, or known hypersensitivity to desmopressin. Caution is also advised for patients with a history of hyponatraemic seizures, uncontrolled heart failure, or those taking other potent antidiuretic agents.